Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA049248-04
Application #
3193297
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1991-07-16
Project End
1994-06-30
Budget Start
1994-01-01
Budget End
1994-06-30
Support Year
4
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Boston University
Department
Type
Schools of Arts and Sciences
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Sulheim, Einar; Kim, Jana; van Wamel, Annemieke et al. (2018) Multi-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models. J Control Release 279:292-305
Wu, Junjie; Waxman, David J (2018) Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Lett 419:210-221
Wu, Junjie; Jordan, Marie; Waxman, David J (2016) Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators. BMC Cancer 16:623
Jordan, Marie; Waxman, David J (2016) CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Cancer Lett 373:88-96
Pantziarka, Pan; Hutchinson, Lisa; André, Nicolas et al. (2016) Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. Ecancermedicalscience 10:689
Haery, Leila; Mussakhan, Sultan; Waxman, David J et al. (2016) Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma. Leuk Lymphoma 57:2661-71
Diep, Phuong; Pannem, Sanjana; Sweer, Jordan et al. (2015) Three-dimensional printed optical phantoms with customized absorption and scattering properties. Biomed Opt Express 6:4212-20
Kareva, Irina; Waxman, David J; Lakka Klement, Giannoula (2015) Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett 358:100-106
Wu, Junjie; Waxman, David J (2015) Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory. Oncoimmunology 4:e1005521
Doloff, Joshua C; Waxman, David J (2015) Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts. BMC Cancer 15:375

Showing the most recent 10 out of 92 publications